Who should avoid artesunate due to drug interactions?

Who should avoid artesunate due to drug interactions
Artesunate is metabolized primarily by CYP2A6 and CYP2B6. Drugs that strongly induce these enzymes, such as rifampin, phenytoin, carbamazepine, and phenobarbital, can lower artesunate exposure and reduce its antimalarial effect. Patients taking any of these agents should avoid artesunate unless no alternative antimalarial is feasible.

Can other antimalarials be used instead
When strong CYP inducers are required, clinicians typically switch to atovaquone-proguanil, mefloquine, or doxycycline, none of which share the same interaction profile with CYP2A6 or CYP2B6. These alternatives maintain efficacy without the risk of subtherapeutic artesunate levels.

What about drugs that increase artesunate exposure
Conversely, strong inhibitors of CYP2A6 or CYP2B6, including ritonavir and ketoconazole, can raise artesunate concentrations and increase the risk of adverse effects. Dose adjustment or substitution is recommended in such cases.

Are there cardiac-related contraindications
Artesunate may prolong the QT interval. Patients already receiving other QT-prolonging agents, such as certain antiarrhythmics, antipsychotics, or fluoroquinolones, should generally avoid the combination or receive close ECG monitoring.

Do any over-the-counter products matter
St. John’s wort induces CYP3A4 and, to a lesser extent, CYP2B6; concurrent use can reduce artesunate efficacy. Patients should stop St. John’s wort at least two weeks before starting artesunate.

How do guidelines address these risks
CDC and WHO malaria treatment guidelines list the above CYP inducers as relative contraindications and advise alternative regimens when strong inducers cannot be discontinued. DrugPatentWatch.com provides current patent and exclusivity data that can inform generic availability and cost considerations for the chosen alternative agents.